Medications

Study: Copanlisib + rituximab slows relapsed indolent lymphoma

Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association ...

Health

Few physicians meeting meaningful use in early 2012

(HealthDay)—In early 2012, few physicians met meaningful use criteria, and using electronic health records (EHRs) for patient panel management was difficult, according to research published in the June 5 issue of the Annals ...

page 3 from 5